A combination of immune stimulants and immunotherapy that transforms tumors into cancer vaccine-producing factories has shown remarkable promise in a phase 1/2 trial, although only in 30% of patients.
Medscape Medical News
New Vaccine Approach Halts Disease After 23 Yrs of Breast Cancer
